Trial Profile
Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2018
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- 27 Jul 2018 Status changed from not yet recruiting to discontinued.
- 14 Oct 2015 New trial record